Research Tools; Pharmaceutical/API Drug Impurities/Metabolites;
應(yīng)用:
BG45 acts as an HDAC class I inhibitor with selectvity for HDAC3. HDACs represent novel targets for anti-tumer drugs treating various cancers including multiple myeloma cancer.